Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bussac

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Cancers|April 12, 2022
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 StudyRenaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, et al.
Annals of Intensive Care|April 18, 2023
ICU admission for solid cancer patients treated with immune checkpoint inhibitorsAnne-Claire Toffart, Anne-Pascale Meert, Florent Wallet, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci studyM Wislez, C Mascaux, J Cadranel, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2019
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French studyCamille Mehlman, Jacques Cadranel, Gaelle Rousseau-Bussac, et al.
Targeted Oncology|November 15, 2023
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)Estelle Dhamelincourt, Renaud Descourt, Gaelle Rousseau-Bussac, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, et al.
Bulletin Du Cancer|June 19, 2022
When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric studyAnne-Pascale Meert, Anne-Claire Toffart, Muriel Picard, et al.
Targeted Oncology|March 13, 2025
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS StudyJean Mourlanette, Gaelle Rousseau-Bussac, Siham Mallah, et al.
Bulletin Du Cancer|February 22, 2023
Erratum to "When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study" [Bull. Cancer 109 (2022) 916-24]Anne-Pascale Meert, Anne-Claire Toffart, Muriel Picard, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Cancers|April 12, 2022
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 StudyRenaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, et al.
Annals of Intensive Care|April 18, 2023
ICU admission for solid cancer patients treated with immune checkpoint inhibitorsAnne-Claire Toffart, Anne-Pascale Meert, Florent Wallet, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci studyM Wislez, C Mascaux, J Cadranel, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2019
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French studyCamille Mehlman, Jacques Cadranel, Gaelle Rousseau-Bussac, et al.
Targeted Oncology|November 15, 2023
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)Estelle Dhamelincourt, Renaud Descourt, Gaelle Rousseau-Bussac, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, et al.
Bulletin Du Cancer|June 19, 2022
When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric studyAnne-Pascale Meert, Anne-Claire Toffart, Muriel Picard, et al.
Targeted Oncology|March 13, 2025
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS StudyJean Mourlanette, Gaelle Rousseau-Bussac, Siham Mallah, et al.
Bulletin Du Cancer|February 22, 2023
Erratum to "When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study" [Bull. Cancer 109 (2022) 916-24]Anne-Pascale Meert, Anne-Claire Toffart, Muriel Picard, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Pageof 5